The Biggest Biotech Stock To Watch In 2024! ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏
| |
| A message from Sideways Frequency |
With record breaking revenues in 2024, it’s hard not to see why Zack’s SCR has called BioStem “a company worth paying attention to” and has issued a price target of $32.50! 2025 could shape to be an incredible year for the biotech arena and one little firm is uniquely standing out for a multitude of reasons. BioStem Technologies (OTC: BSEM) is a leading innovator focused on harnessing the natural properties of perinatal tissue in the development, manufacture, and commercialization of allografts for regenerative therapies. The Company is focused on manufacturing products that change lives, leveraging its proprietary BioREtain® processing method. BioREtain® has been developed by applying the latest research in regenerative medicine, focused on maintaining growth factors and preserving tissue structure. Both the diabetes wound care market and surgical recovery wound care market are growing at a tremendous rate and offer BSEM a big opportunity! A recent study confirmed that BSEM technology is superior and very helpful to patients. 2023 and 2024 marked transformative years for BSEM and last year in particular has showcased the remarkable growth with record-breaking revenue and groundbreaking milestones. The company recently revealed preliminary results that show Q4 net revenue expecting to be $102.9M. This is a whopping 794% increase over Q4 in 2023! Full year net revenue for 2024 is anticipated to be $301.8M, representing a stellar 1,702% growth since fiscal year 2023! BSEM CEO Jason Matuszewski remarked, “Achieving over 1,700% year-over-year revenue growth is a testament to the relentless execution of our strategic initiatives.” Following BSEM’s Q3 results, Zack’s Small Cap Research increased its price target from $24.25 to $32.50! Will Zack’s lift this price target yet again? Discover more about BSEM and its products and why 2025 could be another year of record revenues! This message is a PAID ADVERTISEMENT for BioStem Technologies Inc. (OTC: BSEM) from Sideways Frequency. StockEarnings, Inc. has received a fixed fee of $5,200 from Sideways Frequency for multiple Dedicated Email Sends, Newsletter Sponsorships and SMS Sends between January 15, 2025 and January 21, 2025. Other than the compensation received for this advertisement sent to subscribers, StockEarnings and its principals are not affiliated with either BioStem Technologies Inc. (OTC: BSEM) or Sideways Frequency. StockEarnings and its principals do not own any of the stocks mentioned in this email or in the article that this email links to. Neither StockEarnings nor its principals are FINRA-registered broker-dealers or investment advisers. The content of this email should not be taken as advice, an endorsement, or a recommendation from StockEarnings to buy or sell any security. StockEarnings has not evaluated the accuracy of any claims made in this advertisement. StockEarnings recommends that investors do their own independent research and consult with a qualified investment professional before buying or selling any security. Investing is inherently risky. Past-performance is not indicative of future results. Please see the disclaimer regarding BioStem Technologies Inc. (OTC: BSEM) on Huge Alerts website for additional information about the relationship between Sideways Frequency and BioStem Technologies Inc. (OTC: BSEM).
Your privacy is very important to us, if you wish to be excluded from future notices, do not reply to this message. Instead, please click Unsubscribe.
StockEarnings, Inc
33 SE 4th St, Suite 100, Boca Raton, FL 33432 USA
W: 877.6.STOCKS
StockEarnings.com
|
|
|
| |
